Results of proof-of-concept clinical trials indicate that topiramate can reduce consumption and craving in alcohol-dependent patients who are not yet abstinent. This work is an important step in exploring new types of agents that may have a more potent effect in preventing or reducing drinking, researchers say.
More: FDA Approves Acamprosate | Medical Treatments